Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609).

导出原文传递

翻译打印收藏纠错

作者： Florence,Lerebours ^[1] ; Sofia,Rivera ^[2] ; Marie-Ange,Mouret-Reynier ^[3] ; Severine,Alran ^[4] ; Laurence,Venat-Bouvet ^[5] ; Pierre,Kerbrat ^[6] ; Remy,Salmon ^[4] ; Veronique,Becette ^[7] ; Céline,Bourgier ^[2] ; Pascal,Cherel ^[7] ; Véronique,Boussion ^[3] ; Corinne,Balleyguier ^[2] ; Fabienne,Thibault ^[4] ; Sandrine,Lavau-Denes ^[5] ; Jean-Marc,Nabholz ^[3] ; Brigitte,Sigal ^[4] ; Martine,Trassard ^[7] ; Marie-Christine,Mathieu ^[2] ; Anne-Laure,Martin ^[8] ; Jerome,Lemonnier ^[8] ; Emmanuelle,Mouret-Fourme ^[7]

作者单位： Curie Institute, Saint-Cloud, France. florence.lerebours@curie.fr. ^[1] Gustave Roussy Institute, Villejuif, France. ^[2] Jean Perrin Center, Clermont Ferrand, France. ^[3] Curie Institute, Paris, France. ^[4] Hospital and University Center, Limoges, France. ^[5] Eugene Marquis Center, Rennes, France. ^[6] Curie Institute, Saint-Cloud, France. ^[7] R&D UNICANCER, UCBG, Paris, France. ^[8]

关键词 anastrozole breast cancer breast-conserving surgery clinical response fulvestrant hormone receptor-positive neoadjuvant endocrine therapy phase 2 postmenopausal survival